QuidelOrtho

Q2 FY2026 EarningsQ2 FY26 revenue of $630.9M exceeded the consensus mean of $618.8M (+1.95%), driven by resilient Labs performance and a 16% YoY surge in Point of Care sales. However, adjusted EPS of -$1.36 missed the normalized expectation of -$0.047 primarily due to a 54.2% YoY increase in interest expense and a negative effective tax rate resulting from unbenefited operating losses. Management highlighted ongoing headwinds in China related to pricing guidelines and the finalization of the U.S. donor screening wind-down.